ACRS vs RSKD Comparison

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Riskified Ltd offers an AI-powered e-commerce risk intelligence platform that identifies the individual behind each online interaction for legitimacy, helping merchants (its customers) eliminate risk and uncertainty from their business. The company's core product, the Chargeback Guarantee, automatically approves or declines online orders with performance levels that vary in accordance with its merchants' priorities. Additionally, it offers other products that mitigate similar e-commerce risks for those same merchants, including Policy Protect, Dispute Resolve, and Account Secure. Geographically, Riskified generates maximum revenue from the United States, and the rest from other regions of the Americas, Europe, the Middle East and Africa (EMEA), and the Asia-Pacific (APAC) region.